Taisho drops lead SGLT inhibitor
This article was originally published in Scrip
Executive Summary
Taisho has discontinued a Phase II clinical trial with TS-033, the most advanced compound in its sodium glucose cotransporter (SGLT) portfolio. The company gave no specific reasons for ending the work in Japan and the US with the novel antidiabetic, saying only that it had considered a variety of factors.